Skip to content
Menu

Neuren Pharmaceuticals Limited NURPF

Full chart Compare
Set alert

Price alert · NURPF

All alert types
13.76 USD 0.00 (+0.00%)

Regular-session close

14.00 Day range 14.00
7.70 52-week range 17.25
YTD
+6.58%
1 year
+12.33%

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

213.13 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

6 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C+2 / 5 overall

  • DCF 2
  • Return on Equity 3
  • Return on Assets 4
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E 80.6×
P/S 38.4×
P/B 7.3×
P/FCF 19.8×
EV/EBITDA 112×
EV/Sales 38.3×
FCF Yield 5.1%

Profitability

Gross Margin 100.0%
Operating Margin 34.1%
Net Margin 47.1%
ROE 9.0%
ROIC 5.1%
ROA 8.9%

Growth (YoY)

Revenue -70.2%
Operating Income -84.9%
EPS (diluted) -78.0%
Free Cash Flow 1211.1%

Financial Health

Current Ratio 76.6×
Quick Ratio 76.6×
Debt / Equity 0.0×
Net Debt / EBITDA -0.2×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31